Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Capital Expenditures (2020 - 2023)

Journey Medical (DERM) has disclosed Capital Expenditures for 3 consecutive years, with $5.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Capital Expenditures fell 75.0% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2023, down 75.0%, and an annual FY2024 reading of $15.0 million, up 200.0% over the prior year.
  • Capital Expenditures was $5.0 million for Q1 2023 at Journey Medical, down from $20.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $20.0 million in Q1 2022 and bottomed at $4.1 million in Q4 2020.
  • Average Capital Expenditures over 3 years is $9.7 million, with a median of $5.0 million recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 75.0% in 2023, while the deepest fall reached 75.0% in 2023.
  • Year by year, Capital Expenditures stood at $4.1 million in 2020, then soared by 382.51% to $20.0 million in 2022, then crashed by 75.0% to $5.0 million in 2023.
  • Business Quant data shows Capital Expenditures for DERM at $5.0 million in Q1 2023, $20.0 million in Q1 2022, and $4.1 million in Q4 2020.